Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Siamab Therapeutics Inc.

www.siamab.com

Latest From Siamab Therapeutics Inc.

BI’s Business Development Focus Remains On Early Collaboration

Boehringer Ingelheim’s US business development head Ioannis Sapountzis outlines BI’s efforts to catch up with competitors in NASH and immuno-oncology via early-stage partnerships and licensing deals.

Business Strategies Research and Development Strategies

Deals Shaping The Medical Industry, November 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.

Deals BioPharmaceutical

Deal Watch: AbbVie Bets On Turnstone’s Cancer Immunotherapy Technology

AbbVie takes options on three oncolytic virus immunotherapies under development at Turnstone. Amgen and CytomX swap IP in cancer immunotherapy collaboration, while Nicox and pSivida will team to fight glaucoma and other eye diseases.

Deals Business Strategies

Siamab, BI Team To ‘Attack’ Potential Of Carbohydrate Antibodies In Cancer

With promising preclinical data for lead candidate ST1 in ovarian cancer, Siamab thinks therapeutics targeting tumor-associated carbohydrate antigens will offer potential in multiple solid tumor types.

Deals Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Gc-Free Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Siamab Therapeutics Inc.
  • Senior Management
  • Jeff Behrens, Pres. & CEO
    Dan Dransfield, PhD, SVP, R&D
  • Contact Info
  • Siamab Therapeutics Inc.
    Phone: (617) 714-9773
    90 Bridge Street
    Suite 100
    Newton, MA 02458
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register